The humanization of insulin treatment using the modern NovoPen 4 device improves the quality of life of diabetics in Cuba, Luis Cisneros, general manager of Novo Nordisk for Central America and the Caribbean assured today.
Raising the level of insulin use in the country by changing vials and syringes for a more practical mechanism helps the patient to have a less painful dosage with the use of fine needles, told Prensa Latina the specialist of the Danish company, a world leader in products for diabetics. Although progress has been made in the insulin method since its discovery in 1921, many patients still live with challenges. For this reason, the Cuban Public Health Ministry approved this project three years ago, emphasized Cisneros in the context of the recently concluded I International Diabetes Congress, which brought together about 400 specialists from Latin America, Europe, Asia and the United States. The delivery of NovoPen 4 in Cuba began with a group of 20,000 patients, distributed in several provinces of the country, with priority for type I diabetics of the mother-child program, young people up to 25 years, in addition to people with visual disability or chronic kidney disease, explained the expert. However, it is intended that all Cuban patients have access to this technology in the medium term, until more than 90 percent of the population benefits from this method of applying insulin, he added. The Novo Nordisk specialist stressed that Cuba was the first country in Central America and the Caribbean to use this solution at the institutional level, although he added that the mission of the Danish company is to extend the benefits throughout the region to improve the lives of insulin-dependent patients. This purpose also favors the entire global movement currently underway to reduce the use of plastic, because every year millions of syringes are thrown away, stressed Cisneros.